About ASN

Prabir Roy-Chaudhury, MD, PhD, FASN

ASN Biography

Prabir Roy-Chaudhury MD, PhD, FRCP (Edin) is a Professor of Medicine and the Division Director for Nephrology at the University of Arizona. He is also the Director of the Arizona Kidney and Vascular Center. After graduating from the Armed Forces Medical College, Pune, India, he trained in Internal Medicine and Nephrology at the University of Aberdeen, Scotland and at the Beth Israel Hospital, Harvard Medical School, Boston, USA. In addition to being an active transplant nephrologist, Dr. Roy-Chaudhury?s main research interest is in dialysis vascular access and uremic vascular disease and while at the University of Cincinnati (for over 15 years), he directed the Dialysis Vascular Access Research Program which was a comprehensive, integrated, multi-disciplinary translational research program, which included basic science, clinical science and patient care components. This translational research program was funded through the National Institutes of Health, the Veterans Administration research program and through industry grants. Dr. Roy-Chaudhury has received national and international awards, has published over 150 peer reviewed manuscripts and is a sought after invited speaker, both nationally and internationally.

Dr. Roy-Chaudhury has also been actively involved in the public policy and administrative aspects of dialysis vascular access care and hemodialysis as a board member/councilor/committee chair for the American Society of Diagnostic and Interventional Nephrology, the Renal Network, the Interventional Nephrology Advisory Group of the American Society of Nephrology (ASN), the Cincinnati chapter of the National Kidney Foundation and the Medical Advisory Board of the Life Center (Ohio). He is a member of the ASN Board of Advisors and a member of the ASN Postgraduation Education Committee. Dr. Roy-Chaudhury is also the American Society of Nephrology co-chair of the Kidney Health Initiative which is a public-private partnership between the ASN and the FDA which aims to bring together nephrologists, industry partners, patient advocacy groups and regulatory agencies; in an attempt to facilitate the passage of drugs, devices and biologics into the kidney disease space.

Dr. Roy-Chaudhury is the American Society of Nephrology Co-Chair on the KHI Board of Directors.

Current Position/Titles:

Chief, Division of Nephrology, University of Arizona and Banner University Medical Centers-Tucson and South; Director, Arizona Kidney and Vascular Program; Nephrologist, Southern Arizona VA Health Care Center; American Society of Nephrology Co-Chair, Kidney Health Initiative; President American Nephrologists of Indian Origin; Founder and Chief Scientific Officer, Inovasc LLC

Degrees/Training:

MBBS, Armed Forces Medical College, Pune, India, 1985

MSc (Clinical Pharmacology), University of Aberdeen, Scotland (UK), 1986

Nephrology Fellowship, Beth Israel Hospital, Harvard Medical School, 1996

PhD (Renal Medicine), University of Aberdeen, Scotland (UK), 1997

Internal Medicine Residency, University of Cincinnati, 1998

FRCP (Edin), Royal College of Physicians of Edinburgh, 2000

ASN Service:

ASN Co-Chair, Kidney Health Initiative (KHI) 2012-2018; Member or Chair multiple KHI Committees, 2012-2018; Abstract Selection Committee Member or Chair for Vascular Access x 4 years and Bioengineering x 2 years; ASN Program Committee 2012; ASN PGE Committee, 2012-2018; ASN Board of Advisors and ASN Capitol Hill team 2013-2016; Interventional Nephrology Advisory Group, 2009-2015; X Prize Advisory Panel, 2014; ASN-Industry Innovation Panel, 2015; Co-Chair, Early Program on "Curing Kidney Disease", 2015; ASN Innovation and Discovery Task Force, 2017-2018; ASN-RPA Leadership Panel, 2018

Leadership Positions:

NIH Study Sections: Chair for 10 Special Emphasis Panels for R-21 and SBIR/STTR grants

American Society of Diagnostic and Interventional Nephrology (ASDIN): Councilor 2007-2014; Chair Research Committee 2008-2018; Nominations Committee 2016-2018; International Committee 2013-2018

Vascular Access Society of the Americas: Member, Board of Directors 2008-2013 and 2018 onwards

Cardio Renal Society of the Americas: Member, Board of Directors, 2018 onwards

American Nephrologists of Indian Origin: Secretary, 2009-2015; President 2015 onwards

Editorial Boards: Clinical Nephrology (Section Editor Interventional Nephrology); Scientific Reports; Indian Journal of Nephrology; Journal of Vascular Access

University of Arizona (UA): Research and Innovation Committee; UA-Banner Research Negotiation team, Deans Research Council

Honors:

Glaxo-Chem Prize, University of Aberdeen 1986; 7th John Cunio Memorial Lecture, University of Miami, 2006; Gerald Beathard State of the Art Address, ASDIN, 2011; Gerald Beathard Award, ASDIN, 2012; Health Care Heroes Finalist (Innovator; Cincinnati Business Courier), 2014; KS Chugh Oration, Indian Society of Nephrology 2015, Henry Lecture, Vascular Access Society of the Americas, 2018; Plenary Session talks at the Vascular Access Society (2015), Australia New Zealand Society of Nephrology (2015) and American Society of Artificial and Internal Organs (2018); Faculty election to Alpha Omega Alpha, University of Cincinnati, 2014; National Evidence Generation Committee (Chair Robert Califf, FDA Commissioner), 2016; International Professor, NTR University, Hyderabad, India; 1 US Patent pending, 3 Provisional Patents; 7 Invention Disclosures.

Board Certification:

MRCP (UK) 1988; ABIM Internal Medicine Board Certified 1998; ABIM Nephrology Board Certified 1999

Research Interests:

The main focus of the Arizona Kidney and Vascular Program (AKVP) which I direct, is on "Uremic Vascular Biology", both in the context of vascular access dysfunction and cardiovascular morbidity/mortality in CKD/ESRD patients. AKVP is a patient-centered, multi-disciplinary, translational initiative that includes basic science, translational science and clinical research/outcome domains. We aim to better understand the mechanisms involved in vascular access dysfunction and cardiovascular disease in CKD/ESRD, so that they can be modulated into novel drugs/devices (technology innovation) that target these clinical problems. We have been continuously funded through the NIH and VA for this research over the last decade.

Personal Statement:

It is a distinct personal honor and privilege to have been nominated for ASN Council. I am proud of the fact that I have trained and worked in three countries on three continents (India, the United Kingdom and the US), which has resulted in a more global and inclusive perspective (both for medicine and life). Although we face a large number of challenges in kidney disease, we also live in an era of unprecedented biological and technological innovation which we must apply to kidney disease, while at the same time keeping the patient perspective front and center.